@misc{cherubini_v._long-acting_2016,
	title = {Long-acting {Insulin} {Analogs} {Effect} on gh/igf {Axis} of {Children} with {Type} 1 {Diabetes}: {A} {Randomized}, {Open}-label, {Two}-period, {Cross}-over {Trial}},
	url = {http://www.thieme-connect.com/ejournals/toc/eced},
	abstract = {Background: Growth hormone (GH) secretion is increased in pre-pubertal children with type 1 diabetes and GH excess produces insulin resistance. Early-morning insulinopenia contributes to lower insulin-like growth factor (IGF-I) levels and to GH hypersecretion. Objective: To evaluate differences in GH/IGF-I axis of pre-pubertal children with type 1 diabetes treated with glargine or detemir as long-acting insulin analogues, which was the main outcome measure, and to compare insulin effects in obtaining good metabolic control. Subjects: Children with type 1 diabetes. Methods: This was a 32-week, randomized, open-label, two-period, cross-over comparison between bedtime glargine and twice-daily detemir insulin, involving pre-pubertal children in care at a diabetes pediatric centre. After a 8-week-run-in period subjects were randomized to bedtime glargine or twice-daily detemir insulin administration. After a 12-week period treatments were inverted and continued for additional 12 weeks. Results: Overall, 15 pre-pubertal children (53.3\% males, mean age 8.6+/-1.5 years, duration of diabetes 4.2+/-1.5 years) completed the study. Groups did not differ for GH/IGF axis and HbA1c levels. Treatment with glargine was associated with lower fasting glucose values than treatment with detemir (8.1+/-1.5 vs. 8.2+/-1.7 mmol/L, p=0.01). Incidence rate of hypoglycemia was not different between insulin treatments (IRR=1.18, 95\%CI 1.00-1.38; p=0.07). Detemir treatment was associated with a higher increase in body weight (p=0.008) and height (p=0.02) when compared with glargine. Conclusion: Detemir and glargine not show significant differential effects on the GH/IGFI axis. The greater weight gain and height associated with detemir treatment, apparently not related to the level of pubertal growth, deserve further investigation. Copyright © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart New York.},
	journal = {Experimental and Clinical Endocrinology and Diabetes},
	author = {{Cherubini V.} and {Pintaudi B.} and {Iannilli A.} and {Pambianchi M.} and {Ferrito L.} and {Nicolucci A.}},
	year = {2016},
	keywords = {*growth hormone blood level, *growth hormone/ec [Endogenous Compound], *insulin dependent diabetes mellitus, *insulin dependent diabetes mellitus/dt [Drug Therapy], *insulin detemir/cm [Drug Comparison], *insulin detemir/ct [Clinical Trial], *insulin detemir/dt [Drug Therapy], *insulin glargine/cm [Drug Comparison], *insulin glargine/ct [Clinical Trial], *insulin glargine/dt [Drug Therapy], *long acting insulin, *protein blood level, *somatomedin/ec [Endogenous Compound], Child, article, bedtime dosage, blood glucose monitoring, body height, body weight, clinical article, clinical trial, comparative effectiveness, controlled clinical trial, controlled study, crossover procedure, diabetic patient, female, glucose blood level, glucose/ec [Endogenous Compound], growth hormone, height, hemoglobin A1c, hemoglobin A1c/ec [Endogenous Compound], hemoglobin blood level, human, hypoglycemia, incidence, insulin dependent diabetes mellitus/dt [Drug Therapy], insulin detemir, insulin glargine, insulin treatment, male, open study, pediatric hospital, prepuberty, priority journal, randomized controlled trial, somatomedin C, weight gain}
}

{"_id":"4rX4PpLLp3Z6TiRxn","bibbaseid":"cherubiniv-pintaudib-iannillia-pambianchim-ferritol-nicoluccia-longactinginsulinanalogseffectonghigfaxisofchildrenwithtype1diabetesarandomizedopenlabeltwoperiodcrossovertrial-2016","downloads":0,"creationDate":"2017-05-12T20:20:58.185Z","title":"Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: A Randomized, Open-label, Two-period, Cross-over Trial","author_short":["Cherubini V.","Pintaudi B.","Iannilli A.","Pambianchi M.","Ferrito L.","Nicolucci A."],"year":2016,"bibtype":"misc","biburl":"http://bibbase.org/zotero/gxu917","bibdata":{"bibtype":"misc","type":"misc","title":"Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: A Randomized, Open-label, Two-period, Cross-over Trial","url":"http://www.thieme-connect.com/ejournals/toc/eced","abstract":"Background: Growth hormone (GH) secretion is increased in pre-pubertal children with type 1 diabetes and GH excess produces insulin resistance. Early-morning insulinopenia contributes to lower insulin-like growth factor (IGF-I) levels and to GH hypersecretion. Objective: To evaluate differences in GH/IGF-I axis of pre-pubertal children with type 1 diabetes treated with glargine or detemir as long-acting insulin analogues, which was the main outcome measure, and to compare insulin effects in obtaining good metabolic control. Subjects: Children with type 1 diabetes. Methods: This was a 32-week, randomized, open-label, two-period, cross-over comparison between bedtime glargine and twice-daily detemir insulin, involving pre-pubertal children in care at a diabetes pediatric centre. After a 8-week-run-in period subjects were randomized to bedtime glargine or twice-daily detemir insulin administration. After a 12-week period treatments were inverted and continued for additional 12 weeks. Results: Overall, 15 pre-pubertal children (53.3% males, mean age 8.6+/-1.5 years, duration of diabetes 4.2+/-1.5 years) completed the study. Groups did not differ for GH/IGF axis and HbA1c levels. Treatment with glargine was associated with lower fasting glucose values than treatment with detemir (8.1+/-1.5 vs. 8.2+/-1.7 mmol/L, p=0.01). Incidence rate of hypoglycemia was not different between insulin treatments (IRR=1.18, 95%CI 1.00-1.38; p=0.07). Detemir treatment was associated with a higher increase in body weight (p=0.008) and height (p=0.02) when compared with glargine. Conclusion: Detemir and glargine not show significant differential effects on the GH/IGFI axis. The greater weight gain and height associated with detemir treatment, apparently not related to the level of pubertal growth, deserve further investigation. Copyright © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart New York.","journal":"Experimental and Clinical Endocrinology and Diabetes","author":[{"firstnames":[],"propositions":[],"lastnames":["Cherubini V."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Pintaudi B."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Iannilli A."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Pambianchi M."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Ferrito L."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Nicolucci A."],"suffixes":[]}],"year":"2016","keywords":"*growth hormone blood level, *growth hormone/ec [Endogenous Compound], *insulin dependent diabetes mellitus, *insulin dependent diabetes mellitus/dt [Drug Therapy], *insulin detemir/cm [Drug Comparison], *insulin detemir/ct [Clinical Trial], *insulin detemir/dt [Drug Therapy], *insulin glargine/cm [Drug Comparison], *insulin glargine/ct [Clinical Trial], *insulin glargine/dt [Drug Therapy], *long acting insulin, *protein blood level, *somatomedin/ec [Endogenous Compound], Child, article, bedtime dosage, blood glucose monitoring, body height, body weight, clinical article, clinical trial, comparative effectiveness, controlled clinical trial, controlled study, crossover procedure, diabetic patient, female, glucose blood level, glucose/ec [Endogenous Compound], growth hormone, height, hemoglobin A1c, hemoglobin A1c/ec [Endogenous Compound], hemoglobin blood level, human, hypoglycemia, incidence, insulin dependent diabetes mellitus/dt [Drug Therapy], insulin detemir, insulin glargine, insulin treatment, male, open study, pediatric hospital, prepuberty, priority journal, randomized controlled trial, somatomedin C, weight gain","bibtex":"@misc{cherubini_v._long-acting_2016,\n\ttitle = {Long-acting {Insulin} {Analogs} {Effect} on gh/igf {Axis} of {Children} with {Type} 1 {Diabetes}: {A} {Randomized}, {Open}-label, {Two}-period, {Cross}-over {Trial}},\n\turl = {http://www.thieme-connect.com/ejournals/toc/eced},\n\tabstract = {Background: Growth hormone (GH) secretion is increased in pre-pubertal children with type 1 diabetes and GH excess produces insulin resistance. Early-morning insulinopenia contributes to lower insulin-like growth factor (IGF-I) levels and to GH hypersecretion. Objective: To evaluate differences in GH/IGF-I axis of pre-pubertal children with type 1 diabetes treated with glargine or detemir as long-acting insulin analogues, which was the main outcome measure, and to compare insulin effects in obtaining good metabolic control. Subjects: Children with type 1 diabetes. Methods: This was a 32-week, randomized, open-label, two-period, cross-over comparison between bedtime glargine and twice-daily detemir insulin, involving pre-pubertal children in care at a diabetes pediatric centre. After a 8-week-run-in period subjects were randomized to bedtime glargine or twice-daily detemir insulin administration. After a 12-week period treatments were inverted and continued for additional 12 weeks. Results: Overall, 15 pre-pubertal children (53.3\\% males, mean age 8.6+/-1.5 years, duration of diabetes 4.2+/-1.5 years) completed the study. Groups did not differ for GH/IGF axis and HbA1c levels. Treatment with glargine was associated with lower fasting glucose values than treatment with detemir (8.1+/-1.5 vs. 8.2+/-1.7 mmol/L, p=0.01). Incidence rate of hypoglycemia was not different between insulin treatments (IRR=1.18, 95\\%CI 1.00-1.38; p=0.07). Detemir treatment was associated with a higher increase in body weight (p=0.008) and height (p=0.02) when compared with glargine. Conclusion: Detemir and glargine not show significant differential effects on the GH/IGFI axis. The greater weight gain and height associated with detemir treatment, apparently not related to the level of pubertal growth, deserve further investigation. Copyright © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart New York.},\n\tjournal = {Experimental and Clinical Endocrinology and Diabetes},\n\tauthor = {{Cherubini V.} and {Pintaudi B.} and {Iannilli A.} and {Pambianchi M.} and {Ferrito L.} and {Nicolucci A.}},\n\tyear = {2016},\n\tkeywords = {*growth hormone blood level, *growth hormone/ec [Endogenous Compound], *insulin dependent diabetes mellitus, *insulin dependent diabetes mellitus/dt [Drug Therapy], *insulin detemir/cm [Drug Comparison], *insulin detemir/ct [Clinical Trial], *insulin detemir/dt [Drug Therapy], *insulin glargine/cm [Drug Comparison], *insulin glargine/ct [Clinical Trial], *insulin glargine/dt [Drug Therapy], *long acting insulin, *protein blood level, *somatomedin/ec [Endogenous Compound], Child, article, bedtime dosage, blood glucose monitoring, body height, body weight, clinical article, clinical trial, comparative effectiveness, controlled clinical trial, controlled study, crossover procedure, diabetic patient, female, glucose blood level, glucose/ec [Endogenous Compound], growth hormone, height, hemoglobin A1c, hemoglobin A1c/ec [Endogenous Compound], hemoglobin blood level, human, hypoglycemia, incidence, insulin dependent diabetes mellitus/dt [Drug Therapy], insulin detemir, insulin glargine, insulin treatment, male, open study, pediatric hospital, prepuberty, priority journal, randomized controlled trial, somatomedin C, weight gain}\n}\n\n","author_short":["Cherubini V.","Pintaudi B.","Iannilli A.","Pambianchi M.","Ferrito L.","Nicolucci A."],"key":"cherubini_v._long-acting_2016","id":"cherubini_v._long-acting_2016","bibbaseid":"cherubiniv-pintaudib-iannillia-pambianchim-ferritol-nicoluccia-longactinginsulinanalogseffectonghigfaxisofchildrenwithtype1diabetesarandomizedopenlabeltwoperiodcrossovertrial-2016","role":"author","urls":{"Paper":"http://www.thieme-connect.com/ejournals/toc/eced"},"keyword":["*growth hormone blood level","*growth hormone/ec [Endogenous Compound]","*insulin dependent diabetes mellitus","*insulin dependent diabetes mellitus/dt [Drug Therapy]","*insulin detemir/cm [Drug Comparison]","*insulin detemir/ct [Clinical Trial]","*insulin detemir/dt [Drug Therapy]","*insulin glargine/cm [Drug Comparison]","*insulin glargine/ct [Clinical Trial]","*insulin glargine/dt [Drug Therapy]","*long acting insulin","*protein blood level","*somatomedin/ec [Endogenous Compound]","Child","article","bedtime dosage","blood glucose monitoring","body height","body weight","clinical article","clinical trial","comparative effectiveness","controlled clinical trial","controlled study","crossover procedure","diabetic patient","female","glucose blood level","glucose/ec [Endogenous Compound]","growth hormone","height","hemoglobin A1c","hemoglobin A1c/ec [Endogenous Compound]","hemoglobin blood level","human","hypoglycemia","incidence","insulin dependent diabetes mellitus/dt [Drug Therapy]","insulin detemir","insulin glargine","insulin treatment","male","open study","pediatric hospital","prepuberty","priority journal","randomized controlled trial","somatomedin C","weight gain"],"downloads":0,"html":""},"search_terms":["long","acting","insulin","analogs","effect","igf","axis","children","type","diabetes","randomized","open","label","two","period","cross","over","trial","cherubini v.","pintaudi b.","iannilli a.","pambianchi m.","ferrito l.","nicolucci a."],"keywords":["*growth hormone blood level","*growth hormone/ec [endogenous compound]","*insulin dependent diabetes mellitus","*insulin dependent diabetes mellitus/dt [drug therapy]","*insulin detemir/cm [drug comparison]","*insulin detemir/ct [clinical trial]","*insulin detemir/dt [drug therapy]","*insulin glargine/cm [drug comparison]","*insulin glargine/ct [clinical trial]","*insulin glargine/dt [drug therapy]","*long acting insulin","*protein blood level","*somatomedin/ec [endogenous compound]","child","article","bedtime dosage","blood glucose monitoring","body height","body weight","clinical article","clinical trial","comparative effectiveness","controlled clinical trial","controlled study","crossover procedure","diabetic patient","female","glucose blood level","glucose/ec [endogenous compound]","growth hormone","height","hemoglobin a1c","hemoglobin a1c/ec [endogenous compound]","hemoglobin blood level","human","hypoglycemia","incidence","insulin dependent diabetes mellitus/dt [drug therapy]","insulin detemir","insulin glargine","insulin treatment","male","open study","pediatric hospital","prepuberty","priority journal","randomized controlled trial","somatomedin c","weight gain"],"authorIDs":[],"dataSources":["9LqPNaySNpNxYBFzj"]}